Special Issue: Multiple Myeloma Year in Review

2022 Year in Review - Multiple Myeloma

Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits.
Read More

Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy.
Read More

Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients.
Read More

Page 3 of 3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: